NCT00189956View on ClinicalTrials.gov

Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine.

PHASE2CompletedINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

November 30, 2003

Study Completion Date

December 31, 2005

Conditions
Smallpox
Interventions
BIOLOGICAL

IMVAMUNE (MVA-BN)

Two vaccinations of 0.5 ml MVA-BN vaccine, separated by a 4 week interval.

Trial Locations (1)

4123

Swiss Pharma Contract, Basel

Sponsors

Lead Sponsor

Bavarian Nordic
All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Bavarian Nordic

INDUSTRY